Cryoport (NASDAQ:CYRX) Upgraded to “Buy” at UBS Group

Cryoport (NASDAQ:CYRX) was upgraded by equities researchers at UBS Group from a “neutral” rating to a “buy” rating in a research note issued on Monday,Benzinga reports. The brokerage presently has a $10.00 price objective on the stock. UBS Group’s price target would indicate a potential upside of 75.75% from the stock’s previous close.

Several other equities research analysts have also recently commented on CYRX. Guggenheim started coverage on Cryoport in a research note on Thursday, December 19th. They issued a “buy” rating and a $11.00 target price on the stock. Needham & Company LLC restated a “buy” rating and issued a $11.00 price target on shares of Cryoport in a research note on Wednesday, March 5th. One research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. Based on data from MarketBeat, Cryoport presently has an average rating of “Moderate Buy” and an average price target of $11.67.

Cryoport Stock Down 1.4 %

Shares of NASDAQ CYRX opened at $5.69 on Monday. Cryoport has a 52-week low of $4.58 and a 52-week high of $20.11. The stock has a market cap of $283.99 million, a PE ratio of -1.68 and a beta of 1.67. The company has a debt-to-equity ratio of 0.48, a quick ratio of 5.32 and a current ratio of 5.70. The business has a fifty day moving average of $6.81 and a two-hundred day moving average of $7.37.

Cryoport (NASDAQ:CYRX) last announced its quarterly earnings data on Tuesday, March 4th. The company reported ($0.42) EPS for the quarter, missing analysts’ consensus estimates of ($0.33) by ($0.09). Cryoport had a negative return on equity of 13.35% and a negative net margin of 70.08%. The firm had revenue of $59.53 million during the quarter, compared to analyst estimates of $58.71 million. During the same quarter in the previous year, the business earned ($0.29) earnings per share. As a group, equities research analysts expect that Cryoport will post -0.99 earnings per share for the current fiscal year.

Insider Activity at Cryoport

In related news, CEO Jerrell Shelton sold 4,620 shares of the firm’s stock in a transaction dated Monday, March 17th. The stock was sold at an average price of $6.29, for a total value of $29,059.80. Following the sale, the chief executive officer now directly owns 765,399 shares of the company’s stock, valued at $4,814,359.71. This trade represents a 0.60 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Insiders have sold 14,431 shares of company stock valued at $80,884 over the last ninety days. 10.10% of the stock is owned by corporate insiders.

Institutional Trading of Cryoport

Large investors have recently bought and sold shares of the business. Franklin Resources Inc. boosted its stake in shares of Cryoport by 0.4% during the fourth quarter. Franklin Resources Inc. now owns 387,131 shares of the company’s stock valued at $3,012,000 after purchasing an additional 1,512 shares in the last quarter. Rhumbline Advisers boosted its stake in shares of Cryoport by 2.9% during the fourth quarter. Rhumbline Advisers now owns 63,284 shares of the company’s stock valued at $492,000 after purchasing an additional 1,764 shares in the last quarter. Point72 Asia Singapore Pte. Ltd. boosted its stake in shares of Cryoport by 148.7% during the fourth quarter. Point72 Asia Singapore Pte. Ltd. now owns 3,546 shares of the company’s stock valued at $28,000 after purchasing an additional 2,120 shares in the last quarter. Nebula Research & Development LLC boosted its stake in shares of Cryoport by 21.6% during the fourth quarter. Nebula Research & Development LLC now owns 12,442 shares of the company’s stock valued at $97,000 after purchasing an additional 2,207 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. boosted its stake in shares of Cryoport by 0.6% during the third quarter. Charles Schwab Investment Management Inc. now owns 387,714 shares of the company’s stock valued at $3,144,000 after purchasing an additional 2,226 shares in the last quarter. 92.90% of the stock is owned by institutional investors and hedge funds.

About Cryoport

Cryoport, Inc provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services.